Literature DB >> 32750572

Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study.

Bernadette A Cullen1, Katrina Rodriguez2, William W Eaton2, Ramin Mojtabai3, Tara Von Mach4, Michele L Ybarra5.   

Abstract

This 6 month randomized control trial investigated whether a novel text-messaging program impacted targeted clinical outcomes in patients with schizophrenia and schizoaffective disorder (SAD). Forty patients were enrolled and completed baseline, 3-month and 6-month assessments. The intervention group received daily symptom check-in text messages, plus, a medication reminder or, inspirational quote text. The control group had treatment as usual. At 6 months the Positive and Negative Syndrome Scale mean positive score was significantly lower and injectable medication compliance was significantly higher in the intervention group. Recovery scores were significantly higher at 3 months. Results suggest that this program may benefit individuals with schizophrenia/SAD who use text messaging. Further investigation in a larger sample appears warranted.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32750572      PMCID: PMC7530047          DOI: 10.1016/j.psychres.2020.113346

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  31 in total

1.  Validating the empowerment scale with a multisite sample of consumers of mental health services.

Authors:  E Sally Rogers; Ruth O Ralph; Mark S Salzer
Journal:  Psychiatr Serv       Date:  2010-09       Impact factor: 3.084

2.  A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia.

Authors:  Jose Manuel Montes; Esteban Medina; Manuel Gomez-Beneyto; Jorge Maurino
Journal:  Psychiatry Res       Date:  2012-08-17       Impact factor: 3.222

3.  Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia.

Authors:  Dror Ben-Zeev; Susan M Kaiser; Christopher J Brenner; Mark Begale; Jennifer Duffecy; David C Mohr
Journal:  Psychiatr Rehabil J       Date:  2013-09-09

Review 4.  Advancing recovery science: reliability and validity properties of the Recovery Assessment Scale.

Authors:  Mark S Salzer; Eugene Brusilovskiy
Journal:  Psychiatr Serv       Date:  2014-04-01       Impact factor: 3.084

5.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

Review 6.  Mobile Phone Ownership and Endorsement of "mHealth" Among People With Psychosis: A Meta-analysis of Cross-sectional Studies.

Authors:  Joseph Firth; Jack Cotter; John Torous; Sandra Bucci; Josh A Firth; Alison R Yung
Journal:  Schizophr Bull       Date:  2015-09-22       Impact factor: 9.306

7.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Authors:  Stefan Leucht; Magdolna Tardy; Katja Komossa; Stephan Heres; Werner Kissling; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2012-05-03       Impact factor: 79.321

8.  Course of schizoaffective psychoses: results of a followup study.

Authors:  J Angst; W Felder; B Lohmeyer
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

9.  Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: App4Independence (A4i).

Authors:  Sean A Kidd; Laura Feldcamp; Amos Adler; Linda Kaleis; Wei Wang; Klara Vichnevetski; Kwame McKenzie; Aristotle Voineskos
Journal:  PLoS One       Date:  2019-07-15       Impact factor: 3.240

10.  Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study.

Authors:  Jasper E Palmier-Claus; Anne Rogers; John Ainsworth; Matt Machin; Christine Barrowclough; Louise Laverty; Emma Barkus; Shitij Kapur; Til Wykes; Shôn W Lewis
Journal:  BMC Psychiatry       Date:  2013-01-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.